The GDF15-GFRAL pathway is dispensable for the effects of metformin on energy balance
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Klein et al_Cell Reports_2022_Vol 40(8)_e111258
Forlagets udgivne version, 2,49 MB, PDF-dokument
Metformin is a blood-glucose-lowering medication with physiological effects that extend beyond its anti-diabetic indication. Recently, it was reported that metformin lowers body weight via induction of growth differentiation factor 15 (GDF15), which suppresses food intake by binding to the GDNF family receptor α-like (GFRAL) in the hindbrain. Here, we corroborate that metformin increases circulating GDF15 in mice and humans, but we fail to confirm previous reports that the GDF15-GFRAL pathway is necessary for the weight-lowering effects of metformin. Instead, our studies in wild-type, GDF15 knockout, and GFRAL knockout mice suggest that the GDF15-GFRAL pathway is dispensable for the effects of metformin on energy balance. The data presented here question whether metformin is a sufficiently strong stimulator of GDF15 to drive anorexia and weight loss and emphasize that additional work is needed to untangle the relationship among metformin, GDF15, and energy balance.
Originalsprog | Engelsk |
---|---|
Artikelnummer | 111258 |
Tidsskrift | Cell Reports |
Vol/bind | 40 |
Udgave nummer | 8 |
ISSN | 2211-1247 |
DOI | |
Status | Udgivet - 2022 |
Bibliografisk note
CURIS 2022 NEXS 213
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
- Det Natur- og Biovidenskabelige Fakultet
Forskningsområder
Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk
ID: 317510389